Arcus Biosciences (RCUS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Voting matters and shareholder proposals
Election of four directors: Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier, with board recommending a vote for each nominee.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation as disclosed in the proxy statement.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting scheduled for June 11, 2026.
Audit committee and external auditor matters
Audit Committee has selected Ernst & Young LLP as the external auditor for the upcoming fiscal year, subject to shareholder ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arcus Biosciences
- Q1 2025 net loss was $112M on $28M revenue; cash reserves strong at $1B.RCUS
Q1 20259 Jul 2026 - Castatinopathy demonstrates superior efficacy in RCC trials, targeting major market growth.RCUS
H.C. Wainwright 27th Annual Global Investment Conference9 Jul 2026 - Casdatifan outperforms belzutifan in ccRCC, with strong efficacy, safety, and major market potential.RCUS
Status Update8 Jul 2026 - All proposals passed with quorum established; final results to be published in Form 8-K.RCUS
AGM 202611 Jun 2026 - Casdatifan and quemliclustat drive strong clinical and market prospects with pivotal data ahead.RCUS
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Casdatifan and quemliclustat drive pipeline growth as Q1 net loss widens to $128M.RCUS
Q1 202611 May 2026 - Virtual meeting to vote on directors, auditor, and executive pay, with strong governance and Gilead ties.RCUS
Proxy filing21 Apr 2026 - Casdatifan and quemliclustat drive late-stage pipeline toward major 2026 milestones and markets.RCUS
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Casdatifan achieved 45% ORR and 15.1-month PFS in RCC, with $1B cash supporting pipeline growth.RCUS
Q4 20258 Apr 2026